Papillary Carcinoma of Thyroid Gland in a Patient Treated with Recombinant Growth Hormone
Authors
Abstract:
The first successful treatment of growth hormone (GH) deficient children with GH extracted from human pituitary was introduced during late 1950's. The subsequent availability and use of recombinant GH (rhGH) for different clinical conditions raised the question of whether this new therapeutic modality increases the risk of certain conditions such as leukemia or malignancy. Herein, we report on a 22-year-old man who was diagnosed as a case of GH deficiency at the age of 11 years, was treated with rhGH for 6 years and who developed papillary carcinoma of the thyroid gland 6 years after cessation of the treatment.
similar resources
papillary carcinoma of thyroid gland in a patient treated with recombinant growth hormone
the first successful treatment of growth hormone (gh) deficient children with gh extracted from human pituitary was introduced during late 1950's. the subsequent availability and use of recombinant gh (rhgh) for different clinical conditions raised the question of whether this new therapeutic modality increases the risk of certain conditions such as leukemia or malignancy. herein, we report o...
full textPAPILLARY THYROID CARCINOMA IN MASHHAD
Thyroid cancer is the most common endocrine malignancy. This study surveys the pathologic characteristics of thyroid cancerin Mashhad and study of papillary carcinoma in more detail. In this retrospective study, 108 out of 197 cases of thyroid cancer were papillary in type (55%), with female to male ratio of 1.91 which is lower than current reports. The age at the time of diagnosis ranged ...
full textEctopic papillary thyroid carcinoma in the mediastinum without any tumoral involvement in the thyroid gland. A Case report
Ectopic thyroid tissue results from abnormal embryologic development and migration of the thyroid gland. True malignant transformation in ectopic thyroid tissue is extremely rare and is always diagnosed after surgical excision of the lesion by pathology examinations. There are well-documented cases of ectopic thyroid cancer while primary tumoral lesion occurs in the orthotopic thyroid, but only...
full textStudy of correlation between vascular endothelial growth factor receptor and some prognostic factors in papillary carcinoma of thyroid gland
Background and Objective: Thyroid cancer is the most frequent endocrine malignancy in the world and papillary carcinoma is the most frequent thyroid carcinoma. Different markers used for determination of prognosis and VEGFR is one of them. The aim of present study was to determine the expression of Vascular Endothelial Growth Factor Receptor (VEGFR) as a prognostic marker in papillary carcinoma...
full textHyponatremia after Thyroid Hormone Withdrawal in a Patient with Papillary Thyroid Carcinoma
Hyponatremia is an electrolyte abnormality commonly found in clinical practice. It is important to diagnose the underlying etiology of the hyponatremia and correct it appropriately because severe hyponatremia can cause serious complications and substantially increase the risk of mortality. Although hypothyroidism is known to be a cause of hyponatremia, it is rare that hyponatremia occurs in rel...
full textAn Unusual Case Report: Occurrence of Renal Cell Carcinoma, Basal Cell Carcinoma and Chronic Lymphocytic Leukemia in a Case of Papillary Thyroid Carcinoma Treated with Radioactive Iodine
The standard therapy for thyroid cancer is total or near total thyroidectomy, followed by the administration of radioactive iodine for remnant ablation or residual disease. Patients with radioiodine therapy are predisposed to second malignant neoplasms in organs such as central nervous system (CNS), breast, prostate, kidney, bone marrow, salivary gland, and digestive tract. Exposure to carcinog...
full textMy Resources
Journal title
volume 29 issue 1
pages 45- 46
publication date 2015-10-04
By following a journal you will be notified via email when a new issue of this journal is published.
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023